Suppr超能文献

澳大利亚非酒精性脂肪性肝病患者血清肝纤维化无创检测作为临床结局预后标志物的验证。

Validation of serum non-invasive tests of liver fibrosis as prognostic markers of clinical outcomes in people with fatty liver disease in Australia.

作者信息

Vaz Karl, Kemp William, Majeed Ammar, Lubel John, Magliano Dianna J, Glenister Kristen M, Bourke Lisa, Simmons David, Roberts Stuart K

机构信息

Department of Gastroenterology and Hepatology, Alfred Health, Melbourne, Australia.

The School of Translational Medicine (STM), Monash University, Melbourne, Australia.

出版信息

J Gastroenterol Hepatol. 2025 Jan;40(1):241-249. doi: 10.1111/jgh.16774. Epub 2024 Oct 24.

Abstract

BACKGROUND AND AIM

The validity of non-invasive tests (NITs) of liver fibrosis for the prediction of liver and mortality outcomes in an Australian cohort is unknown. We aimed to verify the utility of available NITs to predict overall and cause-specific mortality and major adverse liver outcome (MALO).

METHODS

This was an analysis from the Crossroads 1 clinic sub-study of a randomly sampled adult cohort from regional Australia between 2001 and 2003. Baseline variables included demographic details, anthropometry, health and lifestyle data, and laboratory tests. Non-alcoholic fatty liver disease (NAFLD) and metabolic-(dysfunction) associated fatty liver disease (MAFLD) were defined by fatty liver index ≥ 60 and other accepted criteria. Outcomes were defined by the International Statistical Classification of Diseases and Related Health Problems 10th Revision codes for linked hospitalization and death registry data. Available serum-based NITs were analyzed as predictors of overall, cardiovascular disease-related, and cancer-related mortality and MALO in those with fatty liver disease (FLD).

RESULTS

In total, 1324 and 1444 participants were included for NAFLD and MAFLD analysis (prevalence 35.4% and 40.7%, respectively). There were 298 deaths (89 cardiovascular disease-related and 98 cancer-related) and 24 MALO over a median 19.7 years of follow-up time. In both forms of FLD, fibrosis-4 index, Steatosis-Associated Fibrosis Estimator score, and Forns fibrosis score consistently had the highest area under the receiver operating characteristic curve (AUROC) for overall and cause-specific mortality, with AUROC > 0.70 for each outcome. However, all had poor discriminatory ability for determining MALO in each FLD.

CONCLUSIONS

Several liver fibrosis NITs perform similarly reasonably well in predicting the risk of mortality outcomes in those with FLD but are poorly discriminatory for MALO prediction.

摘要

背景与目的

在澳大利亚队列中,肝纤维化非侵入性检测(NITs)对肝脏及死亡结局预测的有效性尚不清楚。我们旨在验证现有NITs对总体及特定病因死亡率和主要不良肝脏结局(MALO)的预测效用。

方法

这是对2001年至2003年从澳大利亚地区随机抽取的成年队列的十字路口1诊所子研究进行的分析。基线变量包括人口统计学细节、人体测量学、健康和生活方式数据以及实验室检查。非酒精性脂肪性肝病(NAFLD)和代谢(功能障碍)相关脂肪性肝病(MAFLD)根据脂肪肝指数≥60及其他公认标准进行定义。结局根据国际疾病和相关健康问题统计分类第10次修订版代码,用于关联住院和死亡登记数据。对可用的基于血清的NITs进行分析,作为脂肪肝疾病(FLD)患者总体、心血管疾病相关和癌症相关死亡率及MALO的预测指标。

结果

总共纳入1324名和1444名参与者进行NAFLD和MAFLD分析(患病率分别为35.4%和40.7%)。在中位19.7年的随访期内,有298例死亡(89例与心血管疾病相关,98例与癌症相关)和24例MALO。在两种形式的FLD中,纤维化-4指数、脂肪变性相关纤维化估计评分和Forns纤维化评分在总体和特定病因死亡率方面,始终具有最高的受试者工作特征曲线下面积(AUROC),每个结局的AUROC>0.70。然而,所有这些指标在确定每种FLD的MALO方面的鉴别能力都很差。

结论

几种肝纤维化NITs在预测FLD患者的死亡结局风险方面表现相似且相当不错,但在MALO预测方面鉴别能力较差。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验